データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
158681-13-1- 標準SMILES
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1- InChIKey
JZCPYUJPEARBJL-UHFFFAOYSA-N- 分子式
- C22H21Cl3N4O
- 平均分子量
- 463.8 g/mol
- 単同位体質量
- 462.078094
名称と識別子
- 優先名称
- Rimonabant
- IUPAC
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
- 現地名
- リモナバン
- 英語名
- Rimonabant
- 分子式
- C22H21Cl3N4O
- 分子量
- 463.79
名称と別名
Rimonabant168273-06-1AcompliaZimulti5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamideSR141716SR 141716SR-141716ASR-141716A 2815-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamideDTXSID3046453
名称をさらに表示
リモナバンリモナバントリモナバント (JAN)5-(4-クロロフェニル)-1-(2,4-ジクロロフェニル)-4-メチル-N-(ピペリジン-1-イル)-1H-ピラゾール-3-カルボキサミドN-(ピペリジン-1-イル)-5-(4-クロロフェニル)-1-(2,4-ジクロロフェニル)-4-メチル-1H-ピラゾール-3-カルボアミドN-(1-ピペリジニル)-1-(2,4-ジクロロフェニル)-4-メチル-5-(4-クロロフェニル)-1H-ピラゾール-3-カルボアミドN-ピペリジノ-1-(2,4-ジクロロフェニル)-4-メチル-5-(4-クロロフェニル)-1H-ピラゾール-3-カルボアミドxibuqumrimobrantRimonabanLimonabantrimonabantxUnii-rml78en3xe
RML78EN3XESR-141715-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamideDTXCID1026453CHEBI:349671H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-rimonabantumRefChem:389265
データベース識別子
- CAS
158681-13-1、168273-06-1- PubChem CID
- 104850
- DTXSID
DTXSID3046453- ChEMBL
CHEMBL111- ChEBI
CHEBI:34967- UNII
- RML78EN3XE
- EC Number
- 685-399-5
- Nikkaji
- J649.754C
物性
構造計算による物性補完中
- XLogP
- 6.5
- 極性表面積
- 50.2 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 3
- 回転可能結合数
- 4
- 重原子数
- 30
- 形式電荷
- 0
- 複雑度
- 583
実験および物理化学的性質
Solubility2.00e-03 g/L
Physical DescriptionSolid
物理化学的性質
- 融点
- 154.7 °C · 154.7 °C
- 比重(密度)
- 1.41 · 1.41±0.1 g/cm3(Predicted)
- 貯蔵温度
- RT
- 溶解性
- DMSO (最大 20mg/ml) またはエタノール (最大 20mg/ml) に可溶。
- 酸解離定数(Pka)
- 11.31 · 11.31±0.20(Predicted)
- 外見
- 個体
- 色
- 白い
- 安定性
- -20 °C · 防湿。 -20°C の DMSO またはエタノール溶液で最大 3 か月間保存できます。
- InChI
- InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
- InChIKey
- JZCPYUJPEARBJL-UHFFFAOYSA-N
- SMILES
- N1(C2=CC=C(Cl)C=C2Cl)C(C2=CC=C(Cl)C=C2)=C(C)C(C(NN2CCCCC2)=O)=N1
- CAS データベース
- 168273 · 168273-06-1(CAS DataBase Reference)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]；H371 (50%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]；H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]；H373 (50%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]；H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]
P203, P260, P264, P270, P273, P280, P308+P316, P318, P319, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
危険有害性情報
Hazard Classes and CategoriesRepr. 2 (50%)；STOT SE 2 (50%)；STOT RE 1 (50%)；STOT RE 2 (50%)；Aquatic Chronic 1 (50%)
安全データ
- 危険有害性情報
- コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H372
化学と産業
薬理情報
ATC Code
A - Alimentary tract and metabolism；A08 - Antiobesity preparations, excl. diet products；A08A - Antiobesity preparations, excl. diet products；A08AX - Other antiobesity drugs；A08AX01 - Rimonabant
QA - Alimentary tract and metabolism；QA08 - Antiobesity preparations, excl. diet products；QA08A - Antiobesity preparations, excl. diet products；QA08AX - Other antiobesity drugs；QA08AX01 - Rimonabant
Protein BindingAlmost 100%
Pharmacodynamics
In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo.
Mechanism of Action
Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.
Biological Half-Life6 to 9 days with normal BMI and 16 days if BMI is greater than 30
Metabolism/MetabolitesHepatic, CYP3A4 involved.
MeSH Pharmacological Classification
Agents that increase energy expenditure and weight loss by neural and metabolic regulation.
Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.
Absorption, Distribution and Excretion
関連反応
5 件
化合物ノート
読み込み中…